Complex-specific antibodies and antibody fragments and its use
The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
1. A method to identify an isolated monoclonal antibody, or functional fragment thereof which specifically binds to a complex of a specific cognate antibody and its antigen and does not bind either said cognate antibody or said antigen alone, said method comprising
(a) screening a library of antibodies or antibody fragments against a complex of a specific with against the complex of the specific cognate antibody and its antigen in the presence of the unbound antigen and an antibody different from the specific cognate antibody that has the same isotype as the specific cognate antibody,
(b) isolating a complex of the specific of a specific cognate antibody and its antigen and the bound antibodies or antibody fragments, and
(c) identifying and isolating said bound antibodies or antibody fragments,
wherein screening of the library of antibodies or antibody fragments against the complex of the specific cognate antibody and its antigen is performed in the presence of the unbound antigen and the antibody different from the specific cognate antibody that has the same isotype and framework as the specific cognate antibody.
2. The method according to claim 1 , wherein the epitope of said isolated monoclonal antibody or fragment thereof includes one or more amino acids of a variable region of the specific cognate antibody.
3. The method according to claim 1 , wherein said isolated monoclonal antibody or fragment thereof is a humanized or human monoclonal antibody or fragment.
4. The method according to claim 1 , wherein the antigen is a cytokine or a receptor.
5. The method according to claim 1 , wherein said specific cognate antibody is a murine, chimeric, humanized or human monoclonal antibody or fragment thereof.
6. The method according to claim 5 , wherein the specific cognate antibody or fragment thereof is selected from the group consisting of Adalimumab, MOR103, Rituximab, Trastuzumab, Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Infliximab, Ranibizumab, Ustekinumab, Golimumab, Natalizumab, Ofatumumab, Omalizumab and Panitumumab.